50 Best Ibrance Ad Images in 2020 - BigSpy

Home Page | IBRANCE® (palbociclib) | Safety Info
Get the most out of each appointment. © 2020 Pfizer Inc. All rights reserved. Rx only. July 2020 PP-IBR-USA-3861
Home Page | IBRANCE® (palbociclib) | Safety Info
Please see full Prescribing Information for prescription IBRANCE® capsules or tablets here: bit.ly/30nsqZO IBRANCE may cause serious side effects, including: Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills. Lung problems (pneumonitis). IBRANCE may cause severe inflammation of the lungs during treatment that can lead to death. Tell your doctor right away if you have any new or worsening symptoms, including chest pain, cough with or without mucus, and trouble breathing or shortness of breath. Your doctor may interrupt or stop treatment with IBRANCE completely if your symptoms are severe. Before you take IBRANCE, tell your doctor about all of your medical conditions, including if you: • have fever, chills, or any other signs or symptoms of infection. • have liver or kidney problems. • are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby. o Females who are able to become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose of IBRANCE. Your doctor may ask you to take a pregnancy test before you start treatment with IBRANCE. o Males with female partners who can become pregnant should use effective birth control during treatment with IBRANCE for at least 3 months after the last dose of IBRANCE. • are breastfeeding or plan to breastfeed. It is not known if IBRANCE passes into your breast milk. Do not breastfeed during treatment with IBRANCE and for 3 weeks after the last dose. The most common side effects of IBRANCE incl
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Get the most out of each appointment. © 2020 Pfizer Inc. All rights reserved. Rx only. July 2020 PP-IBR-USA-3861
MedTruth - Patient safety & justice.
Home Page | IBRANCE® (palbociclib) | Safety Info
Please see full Prescribing Information for prescription IBRANCE® capsules or tablets here: bit.ly/30nsqZO INDICATIONS IBRANCE 125 mg capsules and tablets are a prescription medicine used in adults to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with an aromatase inhibitor as the first hormonal based therapy in postmenopausal women or in men, or fulvestrant in people with disease progression following hormonal therapy. IMPORTANT SAFETY INFORMATION IBRANCE may cause serious side effects, including: Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills. Lung problems (pneumonitis). IBRANCE may cause severe inflammation of the lungs during treatment that can lead to death. Tell your doctor right away if you have any new or worsening symptoms, including chest pain, cough with or without mucus, and trouble breathing or shortness of breath. Your doctor may interrupt or stop treatment with IBRANCE completely if your symptoms are severe. Before you take IBRANCE, tell your doctor about all of your medical conditions, including if you: • have fever, chills, or any other signs or symptoms of infection. • have liver or kidney problems. • are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby. o Females who are able to become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose of IBRANCE. Your docto
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Get the most out of each appointment. © 2020 Pfizer Inc. All rights reserved. Rx only. July 2020 PP-IBR-USA-3861
LivingWith: Cancer support
Please see full Prescribing Information for prescription IBRANCE® capsules or tablets here: bit.ly/30nsqZO INDICATIONS IBRANCE 125 mg capsules and tablets are a prescription medicine used in adults to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with an aromatase inhibitor as the first hormonal based therapy in postmenopausal women or in men, or fulvestrant in people with disease progression following hormonal therapy. IMPORTANT SAFETY INFORMATION IBRANCE may cause serious side effects, including: Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills. Lung problems (pneumonitis). IBRANCE may cause severe inflammation of the lungs during treatment that can lead to death. Tell your doctor right away if you have any new or worsening symptoms, including chest pain, cough with or without mucus, and trouble breathing or shortness of breath. Your doctor may interrupt or stop treatment with IBRANCE completely if your symptoms are severe. Before you take IBRANCE, tell your doctor about all of your medical conditions, including if you: • have fever, chills, or any other signs or symptoms of infection. • have liver or kidney problems. • are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby. o Females who are able to become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose of IBRANCE. Your docto
Home Page | IBRANCE® (palbociclib) | Safety Info
Please see full Prescribing Information for prescription IBRANCE® capsules or tablets here: bit.ly/30nsqZO IBRANCE may cause serious side effects, including: Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills. Lung problems (pneumonitis). IBRANCE may cause severe inflammation of the lungs during treatment that can lead to death. Tell your doctor right away if you have any new or worsening symptoms, including chest pain, cough with or without mucus, and trouble breathing or shortness of breath. Your doctor may interrupt or stop treatment with IBRANCE completely if your symptoms are severe. Before you take IBRANCE, tell your doctor about all of your medical conditions, including if you: • have fever, chills, or any other signs or symptoms of infection. • have liver or kidney problems. • are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby. o Females who are able to become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose of IBRANCE. Your doctor may ask you to take a pregnancy test before you start treatment with IBRANCE. o Males with female partners who can become pregnant should use effective birth control during treatment with IBRANCE for at least 3 months after the last dose of IBRANCE. • are breastfeeding or plan to breastfeed. It is not known if IBRANCE passes into your breast milk. Do not breastfeed during treatment with IBRANCE and for 3 weeks after the last dose. The most common side effects of IBRANCE include: • Low red bl
Home Page | IBRANCE® (palbociclib) | Safety Info
Listen to ABC’s Of MBC and Science Of MBC to find information and insights around metastatic breast cancer, on WMBC Radio. PP-O4B-USA-3803
Home Page | IBRANCE® (palbociclib) | Safety Info
Learn about IBRANCE—a prescription treatment. © 2020 Pfizer Inc. All rights reserved. April 2020 PP-IBR-USA-3365
Home Page | IBRANCE® (palbociclib) | Safety Info
Please see full Prescribing Information for prescription IBRANCE® capsules or tablets here: bit.ly/30nsqZO INDICATIONS IBRANCE 125 mg capsules and tablets are a prescription medicine used in adults to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with an aromatase inhibitor as the first hormonal based therapy in postmenopausal women or in men, or fulvestrant in people with disease progression following hormonal therapy. IMPORTANT SAFETY INFORMATION IBRANCE may cause serious side effects, including: Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills. Lung problems (pneumonitis). IBRANCE may cause severe inflammation of the lungs during treatment that can lead to death. Tell your doctor right away if you have any new or worsening symptoms, including chest pain, cough with or without mucus, and trouble breathing or shortness of breath. Your doctor may interrupt or stop treatment with IBRANCE completely if your symptoms are severe. Before you take IBRANCE, tell your doctor about all of your medical conditions, including if you: • have fever, chills, or any other signs or symptoms of infection. • have liver or kidney problems. • are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby. o Females who are able to become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose of IBRANCE. Your doctor may ask you to take a pregnancy test before you start treatment with IBRANCE. o Males with female partners who can become pregnant should use effective birth control during treatment with IBRANCE for at least 3 months after the last dose of IBRANCE. • are breastfeeding or plan to breastfeed. It is not known if IBRANCE passes into your breast milk. Do not breastfeed during treatment with IBRANCE and for 3 weeks after the last dose. The most common side effects of IBRANCE include: • Low red blood cell counts and low platelet counts. Call your doctor right away if you develop any of these symptoms during treatment: o dizziness o shortness of breath o weakness o bleeding or bruising more easily o nosebleeds • infections, tiredness, nausea, sore mouth, abnormalities in liver blood tests, diarrhea, hair thinning or hair loss, vomiting, rash, and loss of appetite. IBRANCE may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider about family planning options before starting IBRANCE if this is a concern for you. These are not all of the possible side effects of IBRANCE. For more information, ask your doctor. Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. IBRANCE and other medicines may affect each other, causing side effects. Do not drink grapefruit juice or eat grapefruit products while taking IBRANCE as they may increase the amount of IBRANCE in your blood. Tell your doctor if you start a new medicine. Take IBRANCE exactly as your doctor tells you. If you take too much IBRANCE, call your doctor right away or go to the nearest hospital emergency room. Ambassadors were asked to share their personal stories about IBRANCE. All content was accurate at the time of publication and may have since changed. © 2020 Pfizer Inc. All rights reserved. Rx only. June 2020 PP-IBR-USA-3817
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Home Page | IBRANCE® (palbociclib) | Safety Info
Please see full Prescribing Information for prescription IBRANCE® capsules or tablets here: bit.ly/30nsqZO IBRANCE may cause serious side effects, including: Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills. Lung problems (pneumonitis). IBRANCE may cause severe inflammation of the lungs during treatment that can lead to death. Tell your doctor right away if you have any new or worsening symptoms, including chest pain, cough with or without mucus, and trouble breathing or shortness of breath. Your doctor may interrupt or stop treatment with IBRANCE completely if your symptoms are severe. Before you take IBRANCE, tell your doctor about all of your medical conditions, including if you: • have fever, chills, or any other signs or symptoms of infection. • have liver or kidney problems. • are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby. o Females who are able to become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose of IBRANCE. Your doctor may ask you to take a pregnancy test before you start treatment with IBRANCE. o Males with female partners who can become pregnant should use effective birth control during treatment with IBRANCE for at least 3 months after the last dose of IBRANCE. • are breastfeeding or plan to breastfeed. It is not known if IBRANCE passes into your breast milk. Do not breastfeed during treatment with IBRANCE and for 3 weeks after the last dose. The most common side effects of IBRANCE include: • Low red blood cell counts and low platelet counts. Call your doctor right away if you develop any of these symptoms during treatment: o dizziness o shortness of breath o weakness o bleeding or bruising more easily o nosebleeds • infections, tiredness, nausea, sore mouth, abnormalities in liver blood tests, diarrhea, hair thinning or hair loss, vomiting, rash, and loss of appetite. IBRANCE may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider about family planning options before starting IBRANCE if this is a concern for you. These are not all of the possible side effects of IBRANCE. For more information, ask your doctor. Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. IBRANCE and other medicines may affect each other, causing side effects. Do not drink grapefruit juice or eat grapefruit products while taking IBRANCE as they may increase the amount of IBRANCE in your blood. Tell your doctor if you start a new medicine. Take IBRANCE exactly as your doctor tells you. If you take too much IBRANCE, call your doctor right away or go to the nearest hospital emergency room. INDICATION IBRANCE 125 mg capsules or tablets is a prescription medicine used in adults to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with an aromatase inhibitor as the first hormonal based therapy in postmenopausal women or in men. © 2020 Pfizer Inc. All rights reserved. April 2020 PP-IBR-USA-3315